Skip to main content
. 2022 Jan 6;6:e2000508. doi: 10.1200/PO.20.00508

FIG 2.

FIG 2.

Survival outcomes by MS and compliance to MTB recommendations. (A) PFS by MS reflecting degree of matching (see Methods; n = 113 patients). The median PFS for the whole cohort was 5.1 months (95% CI, 3.8 to 6.4) and by MS category: 0%-39% 3.9 months (95% CI, 2.9 to 4.8) and 40%-100% 9.3 months (95% CI, 6.8 to 11.8). Higher MS was statistically significantly related to longer PFS (Wilcoxon P = .002). HR was calculated by Cox regression. (B) OS by MS reflecting degree of matching (see Methods; n = 113). The median OS for the whole cohort was 12.9 months (95% CI, 9.0 to 16.8) and by MS category: 0%-39% 11.9 months (95% CI, 9.7 to 14.1) and 40%-100% 18.8 months (95% CI, 14.8 to 22.8; Wilcoxon P = .08). (C) PFS according to the compliance to recommendation of MTB. Median PFS by compliance with MTB recommendation: all recommendations followed 9.0 months (95% CI, 7.7 to 10.3), part of recommendations followed 6.0 months (95% CI, 4.0 to 8.0), and physician's choice (did not follow any recommendations) 4.0 months (95% CI, 2.9 to 5.1; Wilcoxon P = .004). HR was calculated by Cox regression. (D) OS according to the compliance to recommendation of MTB. Median OS by compliance with MTB recommendation: all recommendations followed 17.1 months (95% CI, 10.1 to 24.1), part of recommendations followed 17.8 months (95% CI, 9.2 to 26.4), and physician's choice (did not follow any recommendations) 10.8 months (95% CI, 8.0 to 13.6; Wilcoxon P = .046). HR was calculated by Cox regression. HR, hazard ratio; MS, matching score; MTB, Molecular Tumor Board; OS, overall survival; PFS, progression-free survival.